glp _1 Glucagon-like peptide-1 Oral GLP-1s: benefits beyond weight

Cardiovascular outcome trials have demonstrated reductions in major adverse cardiovascular events in high-risk patients, prompting investigation into their effects on various cardiovascular risk factors, including lipid profiles

Immunity, ion channels and epilepsy

For someone with well-controlled blood pressure, a modest increase may be clinically insignificant

Both peptides come combined in a single vial, so you prepare one vial, not two

Stacked Protocol (Ipamorelin + CJC-1295) Dose: 0.2 0.3 mg Ipamorelin + 0.1 mg CJC-1295 (= 46 clicks) Duration: 8 12 weeks Frequency: 1 2 daily Cycle Interval: 4 weeks off before repeating Goal / Description: Synergistic GHRH + GHRP combination studied for amplified GH pulse and IGF-1 response

(12(7)):005520 doi:10.12890/2025_005520